ABSTRACT
Heteroresistance (HR) is a phenomenon in which minority populations of antibiotic resistant bacteria are maintained in
populations dominated by cells susceptible to that antibiotic. We have shown that HR is often undetected by clinical
diagnostics, but that the subpopulations of resistant cells present in HR can lead to in vivo treatment failure. It is critical to
gain a thorough understanding of HR in order to design more effective and sensitive diagnostics for its detection, and to
guide clinical treatment. One major unaddressed area of investigation is which parameters control the dynamics of the
resistant subpopulations in HR. The goal of Project 3 is to elucidate the dynamics of resistant subpopulations through
experimental testing, supported by quantitative modeling of the pharmaco-, population- and evolutionary dynamics of
heteroresistant bacteria. Importantly, this will include studies of both their dynamics upon antibiotic treatment as well as
the reversion of the population toward susceptibility upon removal of the drug. Toward this end we will develop and
analyze the properties of mathematical models of HR based on the mechanisms of heteroresistance derived from
molecular, genetic and single-cell microfluidic studies in Projects 1 and 2. The parameters used for the numerical analyses
of the properties of these models will be estimated with clinical isolates of HR Enterobacteriaceae (Enterobacter,
Escherichia, Klebsiella) and Acinetobacter baumannii obtained from Core B and studied in depth in Projects 1 and 2. For
each subpopulation we will estimate: (i) parameters of comprehensive pharmacodynamic functions, (ii) the rates of
transition between susceptible and resistant states, and (iii) the fitness costs of these resistant states. Using Hollow Fiber
Bioreactors, batch culture, and microfluidics, we will evaluate how well the models, with independent estimates of their
parameters, fit the pharmacodynamic of HR-bacteria confronted with antibiotics and, with continuous culture devices,
how well these models account for the dynamics of drug treatment of heteroresistant infections. In serial transfer culture
we will estimate the rates of transition to baseline susceptible states following the removal of the antibiotics. Based on the
results of these experiments, and in an iterative process, the models will be modified to make them more accurate and
predictive analogs of the pharmacodynamics of HR. For each HR isolate studied, we will also perform experiments to
determine if the frequency of the resistant subpopulations change as a consequence of antibiotic-mediated selection (i.e. if
the baseline frequency of the resistant cells increases), and elucidate if there are conditions under which HR will be
replaced by permanent resistance. The results from this research will for the first time, provide a broad and detailed
understanding of the dynamics of HR, facilitating an understanding of the parameters that control the frequency
of the resistant subpopulations. These studies will have a major impact on the development of diagnostic procedures to
detect HR and the design of protocols for treating infections with bacteria that exhibit HR to the treating antibiotic.
Public Health Relevance Statement
PROJECT NARRATIVE
In accordance with RFA-AI-20-001, the project narrative should not be completed for the research project.
National Institute of Allergy and Infectious Diseases
CFDA Code
DUNS Number
066469933
UEI
S352L5PJLMP8
Project Start Date
05-March-2021
Project End Date
28-February-2026
Budget Start Date
01-March-2024
Budget End Date
28-February-2025
Project Funding Information for 2024
Total Funding
$283,090
Direct Costs
$199,481
Indirect Costs
$83,609
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Allergy and Infectious Diseases
$283,090
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5U19AI158080-04 5649
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5U19AI158080-04 5649
Patents
No Patents information available for 5U19AI158080-04 5649
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5U19AI158080-04 5649
Clinical Studies
No Clinical Studies information available for 5U19AI158080-04 5649
News and More
Related News Releases
No news release information available for 5U19AI158080-04 5649
History
No Historical information available for 5U19AI158080-04 5649
Similar Projects
No Similar Projects information available for 5U19AI158080-04 5649